Verona Pharma plc
VRNA
$105.27
$0.070.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 44.46% | 94.49% | |||
| Total Other Revenue | -96.02% | 27,677.78% | |||
| Total Revenue | 35.25% | 108.04% | |||
| Cost of Revenue | 39.59% | 67.09% | |||
| Gross Profit | 35.05% | 110.45% | |||
| SG&A Expenses | 4.36% | 53.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.77% | 59.03% | |||
| Operating Income | 228.96% | 41.98% | |||
| Income Before Tax | 171.76% | 35.21% | |||
| Income Tax Expenses | 83.68% | -102.89% | |||
| Earnings from Continuing Operations | 173.05% | 51.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 173.05% | 51.76% | |||
| EBIT | 228.96% | 41.98% | |||
| EBITDA | 235.68% | 42.81% | |||
| EPS Basic | 172.42% | 52.89% | |||
| Normalized Basic EPS | 172.92% | 38.30% | |||
| EPS Diluted | 172.42% | 56.38% | |||
| Normalized Diluted EPS | 168.71% | 38.30% | |||
| Average Basic Shares Outstanding | 0.85% | 2.43% | |||
| Average Diluted Shares Outstanding | 7.04% | 2.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||